AZTherapies 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases   2 Products   3 Trials   37 News 
  • ||||||||||  Review, Journal:  Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China. (Pubmed Central) -  Dec 3, 2022   
    The reuse of drugs or combinations currently under investigation for the psychiatric treatment of Alzheimer's disease, including AXS-05, AVP-786, nabilone, brexpiprazole, methylphenidate, and pimavanserin, could provide physicians with additional treatment options. Although most of these drugs have not been explored in China yet, due to the current development trend in this field in China, it is expected that China will be involved in research on these drugs in the future.
  • ||||||||||  cromolyn sodium/ibuprofen (ALZT-OP1) / AZTherapies
    Journal:  ALZT-OP1: An experimental combination regimen for the treatment of Alzheimer's Disease. (Pubmed Central) -  Jul 31, 2022   
    For Alzheimer's disease (AD) treatment, US FDA granted accelerated approval for aducanumab due to its amyloid-β (Aβ)-lowering effects, notwithstanding the reported poor correlation between amyloid plaque reduction and clinical change for this drug...Long-term follow-up indicated that non-steroidal anti-inflammatory drugs use begun when the brain was still normal may benefit these patients, suggesting that the timing of therapy could be crucial. However, previous clinical failures and the present incomplete understanding of the Aβ pathophysiological role in AD put this novel experimental combination regimen at substantial risk of failure.
  • ||||||||||  inhaled cromolyn sodium (AZT-101) / AZTherapies
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI) (clinicaltrials.gov) -  Mar 3, 2022   
    P2,  N=0, Withdrawn, 
    However, previous clinical failures and the present incomplete understanding of the Aβ pathophysiological role in AD put this novel experimental combination regimen at substantial risk of failure. N=80 --> 0 | Trial completion date: Nov 2021 --> Dec 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2021 --> Dec 2024
  • ||||||||||  inhaled cromolyn sodium (AZT-101) / AZTherapies
    Biomarker, Enrollment change, Trial termination:  A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease (clinicaltrials.gov) -  Nov 8, 2021   
    P2a,  N=12, Terminated, 
    N=80 --> 0 | Trial completion date: Nov 2021 --> Dec 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2021 --> Dec 2024 N=80 --> 12 | Active, not recruiting --> Terminated; Low enrollment
  • ||||||||||  Journal:  Anti-Amyloid-β Protein agents for the treatment of Alzheimer's Disease: An update on emerging drugs. (Pubmed Central) -  Feb 4, 2021   
    The actual results support the hypothesis that elevated Aβ represents an early stage in the AD continuum and demonstrate the feasibility of enrolling these high-risk participants in secondary prevention trials to slow cognitive decline during the AD preclinical stages. However, a series of clinical failures may question further development of Aβ-targeting drugs and the findings from current ongoing Phase III trials will hopefully give light to this critical issue.
  • ||||||||||  cromolyn sodium/ibuprofen (ALZT-OP1) / AZTherapies
    Trial completion:  COGNITE: Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease (clinicaltrials.gov) -  Nov 24, 2020   
    P3,  N=620, Completed, 
    However, a series of clinical failures may question further development of Aβ-targeting drugs and the findings from current ongoing Phase III trials will hopefully give light to this critical issue. Active, not recruiting --> Completed
  • ||||||||||  cromolyn sodium/ibuprofen (ALZT-OP1) / AZTherapies
    Enrollment closed, Trial primary completion date:  COGNITE: Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease (clinicaltrials.gov) -  Jul 24, 2019   
    P3,  N=620, Active, not recruiting, 
    N=500 --> 80 | Trial completion date: Nov 2017 --> Nov 2021 | Trial primary completion date: Aug 2017 --> Aug 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2019 --> Dec 2020
  • ||||||||||  cromolyn sodium/ibuprofen (ALZT-OP1) / AZTherapies
    Trial completion date, Trial primary completion date:  COGNITE: Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease (clinicaltrials.gov) -  Jun 12, 2019   
    P3,  N=600, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2019 --> Dec 2020 Trial completion date: Nov 2019 --> Dec 2020 | Trial primary completion date: Nov 2019 --> Jun 2019